Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV showcases a positive outlook due to its compelling advancements in gene therapy, particularly demonstrated by the strong data from ongoing Phase 1/2 studies of AMT-130 for Huntington's disease, which has garnered broad scientific support and a favorable risk-benefit profile. The company's strategic collaboration with Bristol Myers Squibb for cardiovascular disease treatments further enhances its growth potential, particularly as it has navigated regulatory processes without new concerns regarding manufacturing or safety. Additionally, positive reviews from the Data Monitoring Committee for AMT-260 in the GenTLE trial highlight the company's commitment to expanding its innovative pipeline, thus positioning uniQure for substantial market penetration in the future.

Bears say

The analysis indicates a negative outlook on uniQure NV's stock largely due to the company's ongoing developmental challenges, highlighted by a significant delay in the submission timeline for the Biologics License Application (BLA) for AMT-130, now expected beyond the previously guided 1Q26. Additionally, as a clinical-stage company with no revenue-generating products, uniQure has consistently incurred financial losses since inception, raising concerns about its sustainability and financial health. The competitive landscape further exacerbates these issues, as emerging therapies targeting similar indications pose a risk to market penetration and pricing strategies, adding pressure on the anticipated success of uniQure’s gene therapy pipeline.

uniQure (QURE) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 10 analysts, uniQure (QURE) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.